Press Releases

Open-label, randomized, controlled study will evaluate BT-001, a prescription digital therapeutic (PDT) delivering cognitive behavioral therapy to address behavioral root cause of type 2 diabetes Multi-year study will evaluate effectiveness, durability, healthcare utilization and medication changes

SAN FRANCISCO --(BUSINESS WIRE)--Jan. 20, 2022-- Better Therapeutics, Inc. (“Better Therapeutics”; NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing cognitive behavioral therapy to address root causes of cardiometabolic diseases, today announced that Kevin Appelbaum ,

Pivotal trial of BT-001 in type 2 diabetes fully enrolled; interim data analysis determines trial is adequately powered and should continue to completion without changes; primary endpoint readout expected in Q1 2022 Early clinical discovery study in nonalcoholic fatty liver disease (NAFLD) and

SAN FRANCISCO --(BUSINESS WIRE)--Nov. 30, 2021-- Better Therapeutics, Inc. (“Better Therapeutics”; NASDAQ: BTTX), a prescription digital therapeutics company developing cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced the appointment of Deepti

Primary endpoint data expected in Q1 2022 SAN FRANCISCO --(BUSINESS WIRE)--Nov. 18, 2021-- Better Therapeutics, Inc . (“Better Therapeutics”; NASDAQ: BTTX), a prescription digital therapeutics company developing cognitive behavioral therapy to address the root causes of cardiometabolic diseases,

SAN FRANCISCO --(BUSINESS WIRE)--Nov. 11, 2021-- Better Therapeutics, Inc. (“Better Therapeutics”; NASDAQ: BTTX), a prescription digital therapeutics company developing cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced the appointment of Major

SAN FRANCISCO --(BUSINESS WIRE)--Nov. 4, 2021-- Better Therapeutics, Inc. (“Better Therapeutics”; NASDAQ: BTTX), a prescription digital therapeutics company delivering cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced the appointment of Thiago

Open-label, randomized, controlled real world study will evaluate use of BT-001, a prescription digital therapeutic (“PDT”) designed to treat type 2 diabetes by changing the behaviors that are root causes Mass General Brigham joins the Colorado Prevention Center and Catalyst Health Network to

Trading to commence on Nasdaq on Oct. 29, 2021 , under the ticker symbol BTTX SAN FRANCISCO & NEW YORK --(BUSINESS WIRE)--Oct. 29, 2021-- Better Therapeutics, Inc. , a prescription digital therapeutics (PDT) company delivering cognitive behavioral therapy to address the root causes of

Open-label, real-world study to evaluate the effectiveness of BT-001 in Catalyst’s community-based, clinically integrated, primary care setting SAN FRANCISCO--( BUSINESS WIRE )-- Better Therapeutics, Inc . (“Better Therapeutics”), a prescription digital therapeutics (PDT) company developing